Drug Profile
Fluvastatin extended release - Beijing CoSci Med Tech
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Beijing CoSci Med-Tech
- Class Antihyperlipidaemics; Indoles; Monounsaturated fatty acids
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Cardiovascular disorders; Hyperlipidaemia
Most Recent Events
- 04 Aug 2016 Chemical structure information added
- 22 Jul 2016 Investigation in Cardiovascular disorders in China (PO)
- 22 Jul 2016 Investigation in Hyperlipidaemia in China (PO)